Table 2.
Agreement between 24-h UAE (reference) and other albuminuria measures in the overall population and gender-specific subgroupsa
| Parameter | UAC
|
ACR
|
||
|---|---|---|---|---|
| FMV | SUS | FMV | SUS | |
| Overall (n = 241) | ||||
| r2 | 0.85 | 0.71 | 0.87 | 0.83 |
| P30 | 48.1 | 35.3b | 67.6 | 46.5b |
| Bland-Altman agreement mg/L (SD) | −1.9 (11.0) | 10.1 (19.6)b | −3.1 (8.0) | 4.8 (11.8)b |
| Men (n = 124) | ||||
| r2 | 0.87 | 0.75 | 0.88 | 0.86 |
| P30 | 51.6 | 41.9 | 65.3 | 51.6b |
| Bland-Altman agreement mg/L (SD) | −3.6 (14.4) | 11.8 (24.1)b | −3.6 (10.5) | 4.8 (14.2)b |
| Women (n = 117) | ||||
| r2 | 0.49 | 0.24 | 0.65 | 0.42 |
| P30 | 47.4 | 25.9b | 70.7 | 41.0b |
| Bland-Altman agreement mg/L (SD) | −0.1 (4.5) | 8.4 (13.0)b | −2.6 (3.9) | 4.7 (8.4)b |
a
FMV, first morning void; P30, proportion of measurements within 30% of the value of 24-h UAE, determined by the regression equation; SUS, spot urine sample.
b
P ≤ 0.05 spot urine sample versus first morning void.